يرجى استخدام متصفح الكمبيوتر الشخصي للوصول إلى التسجيل - تداول السعودية
حسنًا
CORRECTED-UPDATE 1-Novo Nordisk hijacks Pfizer with bid for US biotech Metsera
Metsera, Inc. 0.00% Post
فايزر -1.04% Post
داو جونز الصناعي -0.26%
إس آند بي 500 -0.61%
ناسداك -0.93%
Metsera, Inc. MTSR | 70.50 70.50 | 0.00% 0.00% Post |
Pfizer Inc. PFE | 26.58 26.62 | -1.04% +0.15% Post |
Dow Jones Industrial Average DJI | 46558.47 | -0.26% |
S&P 500 index SPX | 6632.19 | -0.61% |
NASDAQ IXIC | 22105.36 | -0.93% |
Corrects in paragraphs 1 and 2 to say September, not 'last week'
COPENHAGEN, Oct 30 (Reuters) - Denmark's Novo Nordisk NOVOb.CO said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera MTSR.O, after Pfizer PFE.N in September made an offer for the company.
Novo said it had offered $56.50 per share in cash for Metsera, corresponding to an enterprise value of $6 billion, while Pfizer in September said it would pay $47.50 per share in cash, representing $4.9 billion in enterprise value.
Both Novo and Metsera also offered contingent value rights (CVRs) that could add several billion dollars to the purchase price, based on the achievement of clinical and regulatory milestones.
(Reporting by Louise Breusch Rasmussen and Jacob Gronholt-Pedersen, editing by Terje Solsvik)
((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))
